240 related articles for article (PubMed ID: 24630270)
1. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
Berry SA; Lichter-Konecki U; Diaz GA; McCandless SE; Rhead W; Smith W; Lemons C; Nagamani SC; Coakley DF; Mokhtarani M; Scharschmidt BF; Lee B
Mol Genet Metab; 2014 May; 112(1):17-24. PubMed ID: 24630270
[TBL] [Abstract][Full Text] [Related]
2. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Smith W; Diaz GA; Lichter-Konecki U; Berry SA; Harding CO; McCandless SE; LeMons C; Mauney J; Dickinson K; Coakley DF; Moors T; Mokhtarani M; Scharschmidt BF; Lee B
J Pediatr; 2013 Jun; 162(6):1228-34, 1234.e1. PubMed ID: 23324524
[TBL] [Abstract][Full Text] [Related]
3. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Lichter-Konecki U; Diaz GA; Merritt JL; Feigenbaum A; Jomphe C; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt B; Rhead W
Mol Genet Metab; 2011 Aug; 103(4):323-9. PubMed ID: 21612962
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Lee B; Rhead W; Diaz GA; Scharschmidt BF; Mian A; Shchelochkov O; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Gargosky S; Mokhtarani M; Berry SA
Mol Genet Metab; 2010 Jul; 100(3):221-8. PubMed ID: 20382058
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry SA; Longo N; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Robinson B; Vockley J
Mol Genet Metab; 2017 Nov; 122(3):46-53. PubMed ID: 28916119
[TBL] [Abstract][Full Text] [Related]
6. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate.
Diaz GA; Krivitzky LS; Mokhtarani M; Rhead W; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Lichter-Konecki U; Bartholomew D; Harding CO; Cederbaum S; McCandless SE; Smith W; Vockley G; Bart SA; Korson MS; Kronn D; Zori R; Merritt JL; C S Nagamani S; Mauney J; Lemons C; Dickinson K; Moors TL; Coakley DF; Scharschmidt BF; Lee B
Hepatology; 2013 Jun; 57(6):2171-9. PubMed ID: 22961727
[TBL] [Abstract][Full Text] [Related]
7. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Longo N; Diaz GA; Lichter-Konecki U; Schulze A; Inbar-Feigenberg M; Conway RL; Bannick AA; McCandless SE; Zori R; Hainline B; Ah Mew N; Canavan C; Vescio T; Kok T; Porter MH; Berry SA
Mol Genet Metab; 2021 Jan; 132(1):19-26. PubMed ID: 33388234
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients.
Diaz GA; Schulze A; Longo N; Rhead W; Feigenbaum A; Wong D; Merritt JL; Berquist W; Gallagher RC; Bartholomew D; McCandless SE; Smith WE; Harding CO; Zori R; Lichter-Konecki U; Vockley J; Canavan C; Vescio T; Holt RJ; Berry SA
Mol Genet Metab; 2019 Aug; 127(4):336-345. PubMed ID: 31326288
[TBL] [Abstract][Full Text] [Related]
9. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
Nagamani SC; Diaz GA; Rhead W; Berry SA; Le Mons C; Lichter-Konecki U; Bartley J; Feigenbaum A; Schulze A; Longo N; Berquist W; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Kronn D; Zori R; Cederbaum S; Merritt JL; Wong D; Coakley DF; Scharschmidt BF; Dickinson K; Marino M; Lee BH; Mokhtarani M
Mol Genet Metab; 2015; 116(1-2):29-34. PubMed ID: 26296711
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
Berry SA; Vockley J; Vinks AA; Dong M; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Perdok R; Robinson B; Holt RJ; Longo N
Mol Genet Metab; 2018 Nov; 125(3):251-257. PubMed ID: 30217721
[TBL] [Abstract][Full Text] [Related]
11. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders.
Burrage LC; Jain M; Gandolfo L; Lee BH; ; Nagamani SC
Mol Genet Metab; 2014; 113(1-2):131-5. PubMed ID: 25042691
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
McGuire BM; Zupanets IA; Lowe ME; Xiao X; Syplyviy VA; Monteleone J; Gargosky S; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt BF
Hepatology; 2010 Jun; 51(6):2077-85. PubMed ID: 20512995
[TBL] [Abstract][Full Text] [Related]
13. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Bart S; Kronn D; Zori R; Cederbaum S; Dorrani N; Merritt JL; Sreenath-Nagamani S; Summar M; Lemons C; Dickinson K; Coakley DF; Moors TL; Lee B; Scharschmidt BF
Mol Genet Metab; 2012 Nov; 107(3):308-14. PubMed ID: 22958974
[TBL] [Abstract][Full Text] [Related]
14. Glutamine and hyperammonemic crises in patients with urea cycle disorders.
Lee B; Diaz GA; Rhead W; Lichter-Konecki U; Feigenbaum A; Berry SA; Le Mons C; Bartley J; Longo N; Nagamani SC; Berquist W; Gallagher RC; Harding CO; McCandless SE; Smith W; Schulze A; Marino M; Rowell R; Coakley DF; Mokhtarani M; Scharschmidt BF
Mol Genet Metab; 2016 Jan; 117(1):27-32. PubMed ID: 26586473
[TBL] [Abstract][Full Text] [Related]
15. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
[TBL] [Abstract][Full Text] [Related]
16. Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders.
Cederbaum SD; Edwards J; Kellmeyer T; Peters Y; Steiner RD
Mol Genet Metab; 2023 Apr; 138(4):107558. PubMed ID: 37004302
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders.
Monteleone JP; Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Berry SA; Lemons C; Dickinson K; Coakley D; Lee B; Scharschmidt BF
J Clin Pharmacol; 2013 Jul; 53(7):699-710. PubMed ID: 23775211
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the treatment of urea cycle disorders using phenylbutyrate metabolite analyses: Still many lessons to learn.
Glinton KE; Minard CG; Liu N; Sun Q; Elsea SH; Burrage LC; Nagamani SCS
Mol Genet Metab; 2023 Nov; 140(3):107699. PubMed ID: 37717413
[TBL] [Abstract][Full Text] [Related]
19. Transition to glycerol phenylbutyrate for the management of urea cycle disorders: clinical experiences.
Sacchini M; Procopio E; Pochiero F; Scaturro G; Daniotti M; Donati MA
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(22):11131-11142. PubMed ID: 38039045
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre.
Yeo M; Rehsi P; Dorman M; Grunewald S; Baruteau J; Chakrapani A; Footitt E; Prunty H; McSweeney M
JIMD Rep; 2023 Sep; 64(5):317-326. PubMed ID: 37701329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
